Nasdaq · Healthcare
MASIMO CORP (MASI)
As-reported financials and recent SEC filings for MASIMO CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.53B
Net income
$-151.5M
Net margin
-9.9%
Diluted EPS
$-2.80
ROE
-21.0%
P/E (TTM)
—
Market cap
—
Debt / equity
0.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $1.53B | $1.40B | $1.28B | $2.04B | $1.24B |
| Gross profit | $945.2M | $794.3M | $765.6M | $1.06B | $808.4M |
| Operating income | $310.0M | $63.0M | $166.0M | $210.0M | $275.8M |
| Net income | $-151.5M | $-304.9M | $81.5M | $143.5M | $229.6M |
| Diluted EPS | $-2.80 | $-5.60 | $1.51 | $2.60 | $3.98 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
15-12G2026-06-22
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →Go deeper on MASI
Search MASIMO CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.